AbstractObjective To compare the efficacy between different modalities in the treatment of positive lymph nodes after radical resection for squamous cell carcinoma of thoracic esophagus (TESCC),and to explore the best treatment mode. The Kaplan-Meier method was used to calculate survival rates. The log-rank test and Cox model were used for univariate and multivariate prognostic analyses,respectively. Methods A retrospective analysis was performed among 548 patients with TESCC who were admitted to our hospital and had positive lymph nodes after radical resection. The efficacy of different treatment methods was evaluated. Propensity scores (PSM) were used to make 1-to-1 patient matching between different treatment groups to further analyze and figure out the best treatment model for patients. The Kaplan-Meier method was used to calculate the overall survival (OS) and disease-free survival (DFS) rates. The log-rank test was used for survival analysis and univariate prognostic analysis. The Cox regression model was used for multivariate prognostic analysis. Results In all patients,the 1-,3-,and 5-year OS rates were 79.9%,38.1% and 28.5%,respectively,while the 1-,3-,and 5-year DFS rates were 68.5%,39.8% and 32.5%,respectively. After 1-to-1 matching based on PSM,there were no differences in general clinical pathological data between the four groups. After PSM,there were significant differences in 1-,3-,and 5-year OS and DFS rates between the surgery alone group,the postoperative radiotherapy group,the postoperative chemotherapy group,and the postoperative chemoradiotherapy (POCRT) group (P=0.000,0.000).There were significant differences in OS and DFS rates between patients with stage N1,N2,and N3 disease (P=0.000,0.000).The result of the Cox multivariate analysis showed that treatment method and N staging were two independent prognostic factors for OS and DFS (P=0.001,0.000,0.025,0.016). Conclusions Patients with positive lymph nodes after radical resection for TESCC have a poor prognosis. Moreover,the prognosis becomes worse with the increase in metastatic lymph nodes. POCRT may improve the survival in those patients. Prospective studies are needed to further confirm those conclusions.
Shen Wenbin,Gao Hongmei,Zhu Shuchai et al. Comparison of different treatment modalities in node-positive patients after radical resection for squamous cell carcinoma of the thoracic esophagus[J]. Chinese Journal of Radiation Oncology, 2018, 27(3): 250-255.
Shen Wenbin,Gao Hongmei,Zhu Shuchai et al. Comparison of different treatment modalities in node-positive patients after radical resection for squamous cell carcinoma of the thoracic esophagus[J]. Chinese Journal of Radiation Oncology, 2018, 27(3): 250-255.
[1] Matsubara Y,Matsubara H.The significance of lymph node status as a prognostic factor for esophageal cancer[J].Surg Today,2011,41(9):1190-1195.DOI:10.1007/s00595-011-4542-y. [2] Vazquez-Sequeiros E,Wang L A,Burgart L,et al. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma[J].Gastroenterology,2002,122(7):1815-1821.DOI:10.1053/gast.2002.33665. [3] Tachibana M,Yoshimura H,Kinugasa S,et al. Postoperative chemotherapy vs.chemoradiotherapy for thoracic esophageal cancer:a prospective randomized clinical trial[J].Eur J Surg Oncol,2003,29(7):580-587.DOI:10.1016/S0748-7983(03)00111-2. [4] Chen JQ,Zhu J,Pan JJ,et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus[J].Ann Thorac Surg,2010,90(2):435-442.DOI:10.1016/j.athoracsur.2010.04.002. [5] Hsu HY,Chao YK,Hsieh CH,et al. Postoperative adjuvant therapy improves survival in pathologic nonresponders after neoadjuvant chemoradiation for esophageal squamous cell carcinoma:a propensity-matched analysis[J].Ann Thorac Surg,2016,102(5):1687-1693.DOI:10.1016/j.athoracsur.2016.05.026. [6] Hsu PK,Huang CS,Wang BY,et al. Survival benefits of postoperative chemoradiation for lymph node-positive esophageal squamous cell carcinoma[J].Ann Thorac Surg,2014,97(5):1734-1741.DOI:10.1016/j.athoracsur.2013.12.041. [7] Siewert JR,Stein HJ,Feith M,et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer:lessons from more than 1,000 consecutive resections at a single center in the western world[J].Ann Surg,2001,234(3):360-367.DOI:10.1097/00000658-200109000-00010. [8] Kitagawa Y,Ando N,Nakamura K,et al. The role of adjuvant chemotherapy for localized squamous cell esophageal cancer:current Japanese standard and the unending role of the drawing board[J].Ann Surg Oncol,2012,19(5):1425-1427.DOI:10.1245/s10434-012-2250-5. [9] Xiao ZF,Yang ZY,Liang J,et al. Value of radiotherapy after radical surgery for esophageal carcinoma:a report of 495 patients[J].Ann Thorac Surg,2003,75(2):331-336.DOI:10.1016/S0003-4975(02)04401-6. [10] Schreiber D,Rineer J,Vongtama D,et al. Impact of postoperative radiation after esophagectomy for esophageal cancer[J].J Thorac Oncol,2010,5(2):244-250.DOI:10.1097/JTO.0b013e3181c5e34f. [11] Shridhar R,Weber J,Hoffe SE,et al. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer:a SEER database analysis[J].J Gastrointest Surg,2013,17(8):1339-1345.DOI:10.1007/s11605-013-2192-7. [12] Worni M,Martin J,Gloor B,et al. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008[J].J Am Call Surg,2012,215(5):643-651.DOI:10.1016/j.jamcollsurg.2012.07.006. [13] Zhang J,Chen HQ,Zhang YW,et al. Adjuvant chemotherapy in oesophageal cancer:a meta-analysis and experience from the shanghai cancer hospital[J].J Int Med Res,2008,36(5):875-882.DOI:10.1177/147323000803600502. [14] Ando N,Iizuka T,Ide H,et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study-JCOG9204[J].J Clin Oncol,2003,21(24):4592-4596.DOI:10.1200/JCO.2003.12.095. [15] Rice TW,Adelstein DJ,Chidel MA,et al. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma[J].J Thorac Cardiovasc Surg,2003,126(5):1590-1596.DOI:10.1016/S0022-5223(03)01025-0. [16] Liu HC,Hung SK,Huang CJ,et al. Esophagectomy for locally advanced esophageal cancer,followed by chemoradiotherapy and adjuvant chemotherapy[J].World J Gastroenterol,2005,11(34):5367-5372.DOI:10.3748/wjg.v11.i34.5367. [17] Matsuda S,Takeuchi H,Kawakubo H,et al. Current advancement in multidisciplinary treatment for resectable cStage Ⅱ/Ⅲ esophageal squamous cell carcinoma in Japan[J].Ann Thorac Cardiovasc Surg,2016,22(5):275-283.DOI:10.5761/atcs.ra.16-00111. [18] Xiao ZF,Yang ZY,Miao YJ,et al. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy:report of 549 cases[J].Int J Radiat Oncol Biol Phys,2005,62(1):82-90.DOI:10.1016/j.ijrobp.2004.08.046. [19] Chen JQ,Pan JJ,Zheng XW,et al. Number and location of positive nodes,postoperative radiotherapy,and survival after esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma[J].Int J Radiat Oncol Biol Phys,2012,82(2):475-482.DOI:10.1016/j.ijrobp.2010.08.037.
2018, Vol. 27 
